Orenitram ER
Drug - Orenitram ER™ (treprostinil extended-release tablet) [United Therapeutics Corp.]
August 2017
Therapeutic area - PAH
Approval criteria
- Patient must be 18 years of age or older AND
- Uptravi is prescribed by, or in consultation with, a cardiologist or pulmonologist AND
- Patient must have a diagnosis of pulmonary arterial hypertension (PAH, WHO Group 1) AND
- Patient has WHO Functional Class II-III symptoms AND
- Patient is not smoking tobacco products AND
- Patient must have tried and failed a calcium channel blocker if they have a positive vasoreactivity test AND
- Patient must have tried and failed sildenafil (Revatio) or taladafil (Adcirca) AND
- Unless pregnant, patient must have tried and failed ambrisentan or bosentan
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411